Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead pushing ahead with plans to merge with immune-mediated disease specialist Alumis. Los Angeles-based Acelyrin ...

Acelyrin had been all set to merge into Alumis—but a surprise offe r by Concentra Biosciences has thrown the deal into doubt. As part of an agreement announced two weeks ago, eye-disease-focused ...

Alumis (ALMS) and ACELYRIN (SLRN) reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases.

The drama introduces a potential choice for Acelyrin shareholders: cash now in a deal with Concentra or a potentially bigger return from the all-stock merger with Alumis. Two weeks after Alumis ...

ACELYRIN (SLRN) announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of ...

ACELYRIN, INC. has announced that its Board of Directors has determined that an unsolicited proposal from Concentra Biosciences is unlikely to lead to a better offer than its planned all-stock ...

Acelyrin (NASDAQ:SLRN) traded sharply lower on Tuesday after the company and its California-based rival Alumis (NASDAQ:ALMS) reaffirmed their commitment to merge in line with their previously ...

SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN ...